Table 2.

Summary of the passive agents discussed in this review

Name	Type	Target	Model (s)	Clinical trial	References
9E4/PRX002/Prasinezumab	Mab	C-terminal	PDGFβ-aSyn mice	Yes	Masliah et al., 2011 [132]
				(see Table 3)	Schenk et al., 2017 [133]
					Jankovic et al., 2018 [134]
5C1, 1H7	Mab	C-terminal	mThy1-aSyn mice	–	Games et al., 2014 [136]
1H7	Mab	C-terminal	LV-aSyn in mThy1-aSyn mice	–	Spencer et al., 2017 [138]
MEDI1341	Mab	C-terminal (monomers and oligomers)	SH-SY5Y cells, LV-aSyn mice, rats, monkeys	Yes	Schofield et al., 2019 [139]
Lu AF82422	Mab	N/A	N/A	Yes	Lundbeck
ABBV-0805	Mab	N/A	N/A	Yes	BioArctic/Abbvie
BIIB054/Cinpanemab	Mab	N-terminal (oligomers and fibrils)	PFFs in M83 and WT mice	Yes	Weihofen et al., 2019 [140]
Brys et al., 2019 [141]
Ab274	Mab	C-terminal	BV-2 cells, PDGFβ-aSyn mice	–	Bae et al., 2012 [112]
Syn303	Mab	N-terminal	Primary neurons, PFFs in WT mice	–	Tran et al., 2014 [142]
mAb47	Mab	Oligomers/protofibrils	Thy1- hA30Pα-syn mice	–	Lindström et al., 2014 [108]
Syn-O1, -O4, -F1	Mab	Full length fibrils	mThy1-aSyn	–	Vaikath et al., 2015 [144]
El-Agnaf et al., 2017 [143]
AB1, AB2	Mab	1: N-terminal 2: C-terminal	AAV-aSyn in rats	–	Shahaduzzaman et al., 2015 [128]
C9B7W and 410C9	Mab	LAG3	PFFs in M83 mice	–	Mao et al., 2016 [80]
D10	scFv	Monomers	HEK293 cells	–	Zhou et al., 2004 [155]
NAC32	scFv	NAC region	ST14A cells	–	Lynch et al., 2008 [156]
Syn-10H	scFv	Oligomers	SH-SY5Y cells	–	Emadi et al., 2009 [110]
sD5-apoB	scFv	Oligomers	SH-SY5Y cells	–	Emadi et al., 2007 [109]
PDGFβ-aSyn mice	Spencer et al., 2014 [114]
W20	scFv	Amyloid assemblies	A53T-aSyn tg mice	–	Zha et al., 2016 [111]
NbSyn87	Nanobody	C-terminal (oligomers and fibrils)	N/A	–	Iljina et al., 2017 [162]
NbSyn87*PEST VH14*EST	Nanobody	NbSyn87: C-terminal VH14: NAC region	AAV5-aSyn in rats	–	Chatterjee et al., 2018 [113]

LV, lentivirus; PFF, preformed fibrils.